[Pubmed] Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future

[RSS-Bot]

CNS Drugs. 2024 Jan 11. doi: 10.1007/s40263-023-01059-8. Online ahead of print.

ABSTRACT

Myasthenia gravis (MG) is a rare autoimmune disease that causes debilitating muscle weakness due to impaired neuromuscular transmission. Since most (about 80-90%) MG patients present autoantibodies against the acetylcholine receptor, standard medical therapy consists of symptomatic treatment with acetylcholinesterase inhibitors (e.g., pyridostigmine). In addition, considering the autoimmune basis of MG, standard therapy includes immunomodulating agents, such as corticosteroids, azathioprine, cyclosporine A, and cyclophosphamide. New strategies have been proposed for the treatment of MG and include complement blockade (i.e., eculizumab, ravulizumab, and zilucoplan) and neonatal Fc receptor antagonism (i.e., efgartigimod and rozanolixizumab). The aim of this review is to provide a detailed overview of the pre- and post-marketing evidence on the five pharmacological treatments most recently approved for the treatment of MG, by identifying both preclinical and clinical studies registered in clinicaltrials.gov. A description of the molecules currently under evaluation for the treatment of MG is also provided.

PMID:38212553 | DOI:10.1007/s40263-023-01059-8


Source: https://pubmed.ncbi.nlm.nih.gov/3821255 ... 6&v=2.18.0